Role and targeting of anaplastic lymphoma kinase in cancer.
Role and targeting of anaplastic lymphoma kinase in cancer.
复制标题
DOI：
10.1186/s12943-018-0776-2
复制
发表时间：
2018-02-19
期刊：
影响因子：
37.3
通讯作者：
Morgillo F
中科院分区：
文献类型：
--
作者：
Della Corte CM;Viscardi G;Di Liello R;Fasano M;Martinelli E;Troiani T;Ciardiello F;Morgillo F
间变性淋巴瘤激酶（ALK）基因激活参与了间变性大细胞淋巴瘤、肺癌、炎性肌纤维母细胞瘤、神经母细胞瘤等多种人类癌症的癌变过程，其激活方式可能是与其他致癌基因（NPM、EML4、TIM等）融合或基因扩增、突变或蛋白过表达。ALK是一种跨膜酪氨酸激酶受体，当配体与其细胞外结构域结合时，经历二聚化和随后的细胞内激酶结构域的自磷酸化。当在癌症中被激活时，它代表了特定抑制剂的靶标，如克里唑替尼、塞瑞替尼、阿勒替尼等，这些抑制剂已被证明对alk阳性患者，特别是alk阳性的非小细胞肺癌有显著的疗效。对这些抑制剂的几种耐药机制已经被描述，新的策略正在进行中，以克服当前ALK抑制剂的局限性。
Anaplastic lymphoma kinase (ALK) gene activation is involved in the carcinogenesis process of several human cancers such as anaplastic large cell lymphoma, lung cancer, inflammatory myofibroblastic tumors and neuroblastoma, as a consequence of fusion with other oncogenes (NPM, EML4, TIM, etc) or gene amplification, mutation or protein overexpression. ALK is a transmembrane tyrosine kinase receptor that, upon ligand binding to its extracellular domain, undergoes dimerization and subsequent autophosphorylation of the intracellular kinase domain. When activated in cancer it represents a target for specific inhibitors, such as crizotinib, ceritinib, alectinib etc. which use has demonstrated significant effectiveness in ALK-positive patients, in particular ALK-positive non- small cell lung cancer. Several mechanisms of resistance to these inhibitors have been described and new strategies are underway to overcome the limitations of current ALK inhibitors.
登录
查看更多内容
影响因子：
28.2
作者：
Friboulet L;Li N;Katayama R;Lee CC;Gainor JF;Crystal AS;Michellys PY;Awad MM;Yanagitani N;Kim S;Pferdekamper AC;Li J;Kasibhatla S;Sun F;Sun X;Hua S;McNamara P;Mahmood S;Lockerman EL;Fujita N;Nishio M;Harris JL;Shaw AT;Engelman JA
通讯作者：
Engelman JA
影响因子：
82.9
作者：
Hrustanovic G;Olivas V;Pazarentzos E;Tulpule A;Asthana S;Blakely CM;Okimoto RA;Lin L;Neel DS;Sabnis A;Flanagan J;Chan E;Varella-Garcia M;Aisner DL;Vaishnavi A;Ou SH;Collisson EA;Ichihara E;Mack PC;Lovly CM;Karachaliou N;Rosell R;Riess JW;Doebele RC;Bivona TG
通讯作者：
Bivona TG
DOI：
10.1056/nejmoa1007056
发表时间：
2010-10-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Butrynski JE;D'Adamo DR;Hornick JL;Dal Cin P;Antonescu CR;Jhanwar SC;Ladanyi M;Capelletti M;Rodig SJ;Ramaiya N;Kwak EL;Clark JW;Wilner KD;Christensen JG;Jänne PA;Maki RG;Demetri GD;Shapiro GI
通讯作者：
Shapiro GI
影响因子：
51.1
作者：
Gadgeel, Shirish M.;Gandhi, Leena;Ou, Sai-Hong Ignatius
通讯作者：
Ou, Sai-Hong Ignatius
影响因子：
28.2
作者：
Drilon A;Siena S;Ou SI;Patel M;Ahn MJ;Lee J;Bauer TM;Farago AF;Wheler JJ;Liu SV;Doebele R;Giannetta L;Cerea G;Marrapese G;Schirru M;Amatu A;Bencardino K;Palmeri L;Sartore-Bianchi A;Vanzulli A;Cresta S;Damian S;Duca M;Ardini E;Li G;Christiansen J;Kowalski K;Johnson AD;Patel R;Luo D;Chow-Maneval E;Hornby Z;Multani PS;Shaw AT;De Braud FG
通讯作者：
De Braud FG